Advances in Chronic Kidney Disease
Volume 17, Issue 1 , Pages 102-110 , January 2010

Management of HIV-Infected Patients With ESRD

  • James E. Novak

      Affiliations

    • Corresponding Author InformationAddress correspondence to James E. Novak, MD, PhD, Henry Ford Health System, CFP-505, 2799 West Grand Boulevard, Detroit, MI 48202.
    • ,
  • Lynda A. Szczech

References 

  1. Screening for HIV: recommendation statement. Ann Intern Med. 2005;143:32–37
  2. Mylonakis E, Paliou M, Lally M, et al. Laboratory testing for infection with the human immunodeficiency virus: established and novel approaches. Am J Med. 2000;109:568–576
  3. Vardinon N, Yust I, Katz O, et al. Anti-HIV indeterminate western blot in dialysis patients: a long-term follow-up. Am J Kidney Dis. 1999;34:146–149
  4. Chou CC, Sun CY, Wu MS. Human immunodeficiency virus (HIV) infection screening in a dialysis unit. Ren Fail. 2007;29:459–461
  5. Marcus R, Favero MS, Banerjee S, et al. Prevalence and incidence of human immunodeficiency virus among patients undergoing long-term hemodialysis. The Cooperative Dialysis Study Group. Am J Med. 1991;90:614–619
  6. Rabb H, Agosti SJ, Pollard S, et al. Activated and regulatory T lymphocyte populations in chronic hemodialysis patients. Am J Kidney Dis. 1994;24:443–452
  7. Ahuja TS, Niaz N, Velasco A, et al. Effect of hemodialysis and antiretroviral therapy on plasma viral load in HIV-1 infected hemodialysis patients. Clin Nephrol. 1999;51:40–44
  8. Celum CL, Robinson NJ, Cohen MS. Potential effect of HIV type 1 antiretroviral and herpes simplex virus type 2 antiviral therapy on transmission and acquisition of HIV type 1 infection. J Infect Dis. 2005;191(Suppl 1):S107–S114
  9. Kaplan JE, Masur H, Holmes KK. Guidelines for preventing opportunistic infections among HIV-infected persons–2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. MMWR Recomm Rep. 2002;51:1–52
  10. Ahuja TS, Kumar S, Mansoury H, et al. Hepatitis B vaccination in human immunodeficiency virus-infected adults receiving hemodialysis. Kidney Int. 2005;67:1136–1141
  11. Mandayam S, Ahuja TS. Dialyzing a patient with human immunodeficiency virus infection: what a nephrologist needs to know. Am J Nephrol. 2004;24:511–521
  12. Weller IV, Williams IG. ABC of AIDS: Treatment of infections. BMJ. 2001;322:1350–1354
  13. Ahuja TS, Borucki M, Grady J. Highly active antiretroviral therapy improves survival of HIV-infected hemodialysis patients. Am J Kidney Dis. 2000;36:574–580
  14. Tourret J, Tostivint I, du Montcel ST, et al. Outcome and prognosis factors in HIV-infected hemodialysis patients. Clin J Am Soc Nephrol. 2006;1:1241–1247
  15. Rodriguez RA, Mendelson M, O'Hare AM, et al. Determinants of survival among HIV-infected chronic dialysis patients. J Am Soc Nephrol. 2003;14:1307–1313
  16. Abbott KC, Swanson SJ, Agodoa LY, et al. Human immunodeficiency virus infection and kidney transplantation in the era of highly active antiretroviral therapy and modern immunosuppression. J Am Soc Nephrol. 2004;15:1633–1639
  17. Hammer SM, Saag MS, Schechter M, et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA. 2006;296:827–843
  18. Kim HH, Daar ES. Newer antiretroviral agents and how to use them. Curr HIV/AIDS Rep. 2009;6:55–62
  19. Havlir DV, Tierney C, Friedland GH, et al. In vivo antagonism with zidovudine plus stavudine combination therapy. J Infect Dis. 2000;182:321–325
  20. Ernest CS, Hall SD, Jones DR. Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther. 2005;312:583–591
  21. Rao TK. Human immunodeficiency virus infection in end-stage renal disease patients. Semin Dial. 2003;16:233–244
  22. Gupta SK, Eustace JA, Winston JA, et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2005;40:1559–1585
  23. Nettles RE, Kieffer TL, Kwon P, et al. Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. JAMA. 2005;293:817–829
  24. Shrivastava D, Rao TK, Sinert R, et al. The efficacy of erythropoietin in human immunodeficiency virus-infected end-stage renal disease patients treated by maintenance hemodialysis. Am J Kidney Dis. 1995;25:904–909
  25. Mouthon L, Guillevin L, Tellier Z. Intravenous immunoglobulins in autoimmune- or parvovirus B19-mediated pure red-cell aplasia. Autoimmun Rev. 2005;4:264–269
  26. Coyne DW, Kapoian T, Suki W, et al. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol. 2007;18:975–984
  27. Kupka R, Msamanga GI, Mugusi F, et al. Iron status is an important cause of anemia in HIV-infected Tanzanian women but is not related to accelerated HIV disease progression. J Nutr. 2007;137:2317–2323
  28. KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis. 2007;50:471–530
  29. Abbott KC, Trespalacios FC, Agodoa LY, et al. HIVAN and medication use in chronic dialysis patients in the United States: Analysis of the USRDS DMMS Wave 2 study. BMC Nephrol. 2003;4:5
  30. Haug CJ, Aukrust P, Haug E, et al. Severe deficiency of 1,25-dihydroxyvitamin D3 in human immunodeficiency virus infection: association with immunological hyperactivity and only minor changes in calcium homeostasis. J Clin Endocrinol Metab. 1998;83:3832–3838
  31. Cockerell CJ, Dolan ET. Widespread cutaneous and systemic calcification (calciphylaxis) in patients with the acquired immunodeficiency syndrome and renal disease. J Am Acad Dermatol. 1992;26:559–562
  32. Wang P-H, Chu P-L, Wu C-C, et al. Calciphylaxis in a continuous ambulatory peritoneal dialysis patient after graft failure of cadaveric kidney transplantation. Acta Nephrol. 2001;15:77–80
  33. Petrosillo N, Puro V, Jagger J, et al. The risks of occupational exposure and infection by human immunodeficiency virus, hepatitis B virus, and hepatitis C virus in the dialysis setting. Italian Multicenter Study on Nosocomial and Occupational Risk of Infections in Dialysis. Am J Infect Control. 1995;23:278–285
  34. Updated US. Public Health Service Guidelines for the Management of Occupational Exposures to HBV, HCV, and HIV and Recommendations for Postexposure Prophylaxis. MMWR Recomm Rep. 2001;50:1–52
  35. HIV transmission in a dialysis center–Colombia, 1991-1993. MMWR Morb Mortal Wkly Rep. 1995;44:404–405411–402
  36. Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR Recomm Rep. 2001;50:1–43
  37. Farzadegan H, Ford D, Malan M, et al. HIV-1 survival kinetics in peritoneal dialysis effluent. Kidney Int. 1996;50:1659–1662
  38. Sreedhara R. Characteristics of peritonitis in HIV-positive PD patients. Semin Dial. 2000;13:338
  39. Tebben JA, Rigsby MO, Selwyn PA, et al. Outcome of HIV infected patients on continuous ambulatory peritoneal dialysis. Kidney Int. 1993;44:191–198
  40. Khanna R, Tachopoulou OA, Fein PA, et al. Survival experience of peritoneal dialysis patients with human immunodeficiency virus: a 17-year retrospective study. Adv Perit Dial. 2005;21:159–163
  41. Mitchell D, Krishnasami Z, Young CJ, et al. Arteriovenous access outcomes in haemodialysis patients with HIV infection. Nephrol Dial Transplant. 2007;22:465–470
  42. Brock JS, Sussman M, Wamsley M, et al. The influence of human immunodeficiency virus infection and intravenous drug abuse on complications of hemodialysis access surgery. J Vasc Surg. 1992;16:904–910discussion 911–902
  43. Gorski TF, Gorski YC, Muney J. Complications of hemodialysis access in HIV-positive patients. Am Surg. 2002;68:1104–1106
  44. Schild AF, Perez EA, Gillaspie E, et al. Use of the Vectra polyetherurethaneurea graft for dialysis access in HIV-positive patients with end-stage renal disease. Vasc Endovascular Surg. 2007;41:506–508
  45. Mokrzycki MH, Schroppel B, von Gersdorff G, et al. Tunneled-cuffed catheter associated infections in hemodialysis patients who are seropositive for the human immunodeficiency virus. J Am Soc Nephrol. 2000;11:2122–2127
  46. Schwartz EJ, Fierer DS, Neumann AU, et al. HIV-1 dynamics in haemodialysis patients. AIDS. 2002;16:1301–1303
  47. Stock P, Roland M, Carlson L, et al. Solid organ transplantation in HIV-positive patients. Transplant Proc. 2001;33:3646–3648
  48. Sankatsing SU, Jurriaans S, van Swieten P, et al. Highly active antiretroviral therapy with or without mycophenolate mofetil in treatment-naive HIV-1 patients. AIDS. 2004;18:1925–1931
  49. Sankatsing SU, Hoggard PG, Huitema AD, et al. Effect of mycophenolate mofetil on the pharmacokinetics of antiretroviral drugs and on intracellular nucleoside triphosphate pools. Clin Pharmacokinet. 2004;43:823–832
  50. Izzedine H, Launay-Vacher V, Baumelou A, et al. Antiretroviral and immunosuppressive drug-drug interactions: an update. Kidney Int. 2004;66:532–541
  51. Carter JT, Melcher ML, Carlson LL, et al. Thymoglobulin-associated Cd4 + T-cell depletion and infection risk in HIV-infected renal transplant recipients. Am J Transplant. 2006;6:753–760
  52. Fischereder M, Luckow B, Hocher B, et al. CC chemokine receptor 5 and renal-transplant survival. Lancet. 2001;357:1758–1761
  53. Meanwell NA, Kadow JF. Maraviroc, a chemokine CCR5 receptor antagonist for the treatment of HIV infection and AIDS. Curr Opin Investig Drugs. 2007;8:669–681
  54. Trullas JC, Cofan F, Cocchi S, et al. Effect of thymoglobulin induction on HIV-infected renal transplant recipients: Differences between HIV-positive and HIV-negative patients. AIDS Res Hum Retroviruses. 2007;23:1161–1165
  55. Roland ME, Barin B, Carlson L, et al. HIV-infected liver and kidney transplant recipients: 1- and 3-year outcomes. Am J Transplant. 2008;8:355–365
  56. Gruber SA, Doshi MD, Cincotta E, et al. Preliminary experience with renal transplantation in HIV+ recipients: low acute rejection and infection rates. Transplantation. 2008;86:269–274
  57. Ballarin R, Di Benedetto F, Masetti M, et al. Combined liver-kidney transplantation in an HIV-HCV-coinfected patient with haemophilia. AIDS. 2008;22:2047–2049
  58. Heredia A, Gilliam B, Latinovic O, et al. Rapamycin reduces CCR5 density levels on CD4 T cells, and this effect results in potentiation of enfuvirtide (T-20) against R5 strains of human immunodeficiency virus type 1 in vitro. Antimicrob Agents Chemother. 2007;51:2489–2496
  59. Samonakis DN, Cholongitas E, Triantos CK, et al. Sustained, spontaneous disappearance of serum HCV-RNA under immunosuppression after liver transplantation for HCV cirrhosis. J Hepatol. 2005;43:1091–1093

PII: S1548-5595(09)00173-6

doi: 10.1053/j.ackd.2009.08.014

Advances in Chronic Kidney Disease
Volume 17, Issue 1 , Pages 102-110 , January 2010

Article Tools